drugset

drugset / Trial / NCT06588153

A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China

NCT06588153 ↗

Phase 4 Active not recruiting 102 enrolled Amgen

NaSingle-groupOpen-labelTreatment

Summary

The main objective of this study is to evaluate the efficacy of Prolia® in improving bone mass density (BMD) of lumbar spine at month 12.

Timeline

Start: 2025-05-24
Primary completion: 2027-04-27
Completion: 2027-04-27

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Denosumab	Monoclonal antibody	—	Subcutaneous

Indications